Navigation Links
Drug offers promising approach to improve outcome for children with high-risk leukemia
Date:11/15/2013

Combining the drug gemtuzumab ozogamicin (GO) with conventional chemotherapy may improve the outcome of bone marrow transplantation for some children battling high-risk acute myeloid leukemia (AML), according to a study led by St. Jude Children's Research Hospital. The results appear in the current edition of the journal Cancer.

For young AML patients with suitable bone marrow donors, transplantation offers the best chance of a cure. Being free of even low levels of detectable cancer cells prior to transplantation is associated with better patient survival. This analysis found that combination therapy helped to eliminate minimal residual disease (MRD) in young AML patients who initially had a poor response to chemotherapy. By reducing MRD levels prior to transplantation, it is likely that GO contributed to the excellent outcome of these patients, researchers said.

The drug, trade named Mylotarg, received accelerated approval from the U.S. Food and Drug Administration in 2000 for treatment of AML in adults. The drug was voluntarily withdrawn in 2010 following questions about its safety and efficacy. Since then several studies conducted while the drug was authorized reported promising results in adults with AML. Those reports prompted this analysis of pediatric AML patients who received GO in a clinical trial conducted while the drug was available.

Researchers said the results add to evidence that both adults and children battling AML may benefit from treatments that use a similar mechanism as GO to combat AML. The drug was not associated with severe toxicity in this or other recent studies.

Unlike traditional chemotherapy that kills rapidly dividing cells, both malignant and healthy, GO was designed to kill more selectively. The drug works by targeting a protein carried on the surface of about 90 percent of AML cells. Work has begun on new strategies, including antibody-based therapies, that target the same AML surface protein, said the study's senior author Jeffrey Rubnitz, M.D., Ph.D., a member of the St. Jude Department of Oncology.

AML is diagnosed in about 500 children annually and accounts for about 20 percent of childhood leukemia. The disease affects white blood cells.

"Currently there are few options for AML patients who relapse or do not respond to conventional therapy," said first author Carol O'Hear, M.D., Ph.D., a St. Jude postdoctoral oncology fellow. Added Rubnitz: "Without new agents, it is unlikely we will be able to improve pediatric AML survival beyond current levels of about 70 percent. The results of this and earlier studies make a strong case that some patients benefit from this targeted therapy, which has us looking for new ways to take aim at the same protein."

This study involved a subset of patients enrolled in a clinical trial of pediatric AML called AML02. Altogether, 232 children with AML enrolled in the six-year, multicenter trial that ended in 2008. A total of 46 patients received GO alone or in combination with conventional chemotherapy.

For this analysis, researchers wanted to know if GO was associated with reduced MRD. Patients were considered free of MRD if less than one cancer cell could be detected in 1,000 normal bone marrow cells.

Seventeen patients received GO alone when MRD was detected after two rounds of chemotherapy with the drugs cytarabine, daunorubicin and etoposide. After GO treatment, leukemia declined in 14 of the 17 patients and fell to undetectable levels in 13 patients.

An additional 29 patients received GO as part of their second round of three-drug chemotherapy. All had levels of residual disease that indicated a poor initial response to chemotherapy alone, including nine with MRD levels of 25 percent or more. Residual disease fell to undetectable levels in four of the nine patients following combination therapy.

Malignant cells fell to undetectable levels in 45 percent, or nine of the remaining 20 patients whose second round of treatment included GO plus chemotherapy. The patients all had MRD of between 1 and 25 percent after the first round of chemotherapy.

The overall five-year survival level of the 20 patients was 55 percent, compared to 36 percent for 22 patients with similar MRD who received chemotherapy alone. The survival difference between the two groups was not statistically significant, but investigators said the results point to a possible benefit of GO treatment for some pediatric AML patients whose cancer remained following chemotherapy. The 22 patients were treated early in AML02 before the protocol was revised to expand the use of GO. The revision followed evidence that the drug was well tolerated by the young AML patients.


'/>"/>

Contact: Summer Freeman
summer.freeman@stjude.org
901-595-3061
St. Jude Children's Research Hospital
Source:Eurekalert  

Related medicine news :

1. Absolute Bird Control Offers Complete Line of Woodpecker Deterrents
2. Spectrum Surgical Offers a Range of Surgical Instrument Education Programs and Products for Ongoing Training and to Make Patients Safer
3. Medorizon Offers EMR and ICD-10 Training to Help Medical Community with Change
4. 4leafcity.com Is Launching Special Offers On Its Cardigan Sweaters For Men
5. UC Davis Children's Hospital Offers Access to Pediatric Subspecialty Care for Rural Newborns With PEANUT Program
6. Winter Issue of ChopChop Magazine Offers Edible Gift Ideas for Kids to Make for Family and Friends
7. Asbestos Found in Winnebago County Jail, Florida Asbestos Testing Company AGC Environmental Offers Tip How to Avoid the Mineral Fiber's Fatal Health Effects
8. Goji Advance Weight Loss Formula Offers and Deals: Now Customers Can Get One Extra Bottle on Select Packages
9. Venapro: The Natural Hemorrhoids Treatment Product Now Offers 50% Discount on Select Packages for Limited Time
10. Adventure To Fitness Offers Trial Weekend For Thanksgiving
11. Best Mattress Brand Offers Tips for Winter Health and Better Sleep in Latest Article
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug offers promising approach to improve outcome for children with high-risk leukemia
(Date:10/13/2017)... ... ... While it’s often important to take certain medications during the night, finding ... identified a solution. , She developed a prototype for MOTION LIGHT-UP PILL BOX to ... the need to turn on a light when taking medication during the night, allowing ...
(Date:10/13/2017)... Nevada (PRWEB) , ... October 13, 2017 , ... ... Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil ... required and providing a CBD form that can be easily incorporated into liquid products, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , which ... evacuation of the facility as part of a disaster drill on October 3rd. , ... and Shelton City Emergency Manager, as well as the Connecticut Long Term Care ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network ... advocate for action towards gender equality at their inaugural Summit in New York City ... and reached a social audience of over 3 million. To watch the Mobilize Women ...
(Date:10/13/2017)... ... 2017 , ... Talented host, actor Rob Lowe, is introducing ... new episode of "Success Files," which is an award-winning educational program broadcasted on ... subject in-depth with passion and integrity. , Sciatica occurs when the sciatic nerve ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Oct. 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Software and Consulting, LLC , and named its founder ... based in Tennessee , will operate ... expands EnvoyHealth,s service offerings for health care partners to ... "In an interoperable world, technology ...
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, ... formed by Walgreens and pharmacy benefit manager Prime Therapeutics ... new brand, which included the unveiling of new signage ... , as well as at a few other company-owned ... new brand to patients, some of whom will begin ...
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile ... the struggle to reverse the tide of prescription drug addiction. ... regulating their medicine intake and stepping down their dosage in ... to launch in December 2017; the first 100,000 people to ... more at http://www.rebound-solution.com/ ...
Breaking Medicine Technology: